Cabaletta Bio to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary

Cabaletta Bio, Inc. (Nasdaq: CABA) to present at 42nd Annual J.P. Morgan Healthcare Conference

PHILADELPHIA, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies for patients with autoimmune diseases, today announced that Steven Nichtberger, M.D., Chief Executive Officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024, at 5:15 p.m. PT (8:15 p.m. ET) in San Francisco, CA.

A live webcast of the presentation will be available on the News and Events section of the Company’s website at www.cabalettabio.com. Replays will be available on the website for 30 days.

About Cabaletta Bio
Cabaletta Bio (Nasdaq: CABA) is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies that have the potential to provide a deep and durable, perhaps curative, treatment for patients with autoimmune diseases. The CABA™ platform encompasses two strategies: the CARTA (chimeric antigen receptor T cells for autoimmunity) strategy, with CABA-201, a 4-1BB-containing fully human CD19-CAR T, as the lead product candidate being evaluated in systemic lupus erythematosus, myositis, systemic sclerosis and generalized myasthenia gravis, and the CAART (chimeric autoantibody receptor T cells) strategy, with multiple clinical-stage candidates, including DSG3-CAART for mucosal pemphigus vulgaris and MuSK-CAART for MuSK myasthenia gravis. The expanding CABA™ platform is designed to develop potentially curative therapies that offer deep and durable responses for patients with a broad range of autoimmune diseases. Cabaletta Bio’s headquarters and labs are located in Philadelphia, PA.

Contacts:

Anup Marda
Chief Financial Officer
investors@cabalettabio.com

William Gramig
Stern Investor Relations, Inc.
william.gramig@sternir.com

FAQ

What is the latest announcement from Cabaletta Bio, Inc. (Nasdaq: CABA)?

Cabaletta Bio, Inc. (Nasdaq: CABA) announced that their CEO, Steven Nichtberger, M.D., will present at the 42nd Annual J.P. Morgan Healthcare Conference on January 9, 2024.

When and where will the presentation take place?

The presentation will take place on Tuesday, January 9, 2024, at 5:15 p.m. PT (8:15 p.m. ET) in San Francisco, CA.

Where can I watch the live webcast of the presentation?

The live webcast of the presentation will be available on the News and Events section of the Company’s website at www.cabalettabio.com.

How long will the replays of the presentation be available?

Replays of the presentation will be available on the website for 30 days.